Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Arena Pharmaceuticals stock | 66.15

Own Arena Pharmaceuticals stock in just a few minutes.

Posted

Fact checked

Arena Pharmaceuticals, Inc is a biotechnology business based in the US. Arena Pharmaceuticals shares (ARNA) are listed on the NASDAQ and all prices are listed in US Dollars. Arena Pharmaceuticals employs 320 staff and has a trailing 12-month revenue of around USD$4.6 million.

How to buy shares in Arena Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Arena Pharmaceuticals. Find the stock by name or ticker symbol: ARNA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Arena Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$66.15, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Arena Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Arena Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Arena Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Arena Pharmaceuticals's share price has had significant positive movement.

Its last market close was USD$66.15, which is 20.35% up on its pre-crash value of USD$52.69 and 100.76% up on the lowest point reached during the March crash when the shares fell as low as USD$32.95.

If you had bought USD$1,000 worth of Arena Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$842.36 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,394.44.

Arena Pharmaceuticals share price

Use our graph to track the performance of ARNA stocks over time.

Arena Pharmaceuticals shares at a glance

Information last updated 2020-10-20.
Latest market close USD$66.15
52-week range USD$32.95 - USD$86.58
50-day moving average USD$73.2974
200-day moving average USD$62.7051
Wall St. target price USD$93.15
PE ratio 6.3979
Dividend yield N/A (0%)
Earnings per share (TTM) USD$10.836

Buy Arena Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Arena Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arena Pharmaceuticals price performance over time

Historical closes compared with the close of $66.15 from 2020-11-16

1 week (2020-11-20) 2.04%
1 month (2020-10-30) -22.83%
3 months (2020-08-28) -6.01%
6 months (2020-05-29) 10.67%
1 year (2019-11-29) 39.62%
2 years (2018-11-29) 62.45%
3 years (2017-11-29) 117.31%
5 years (2015-11-27) 2,976.74%

Is Arena Pharmaceuticals under- or over-valued?

Valuing Arena Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Arena Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Arena Pharmaceuticals's P/E ratio

Arena Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Arena Pharmaceuticals shares trade at around 6x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Arena Pharmaceuticals's PEG ratio

Arena Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.46. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Arena Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Arena Pharmaceuticals's EBITDA

Arena Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$549.8 million.

The EBITDA is a measure of a Arena Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Arena Pharmaceuticals financials

Revenue TTM USD$4.6 million
Gross profit TTM USD$574.9 million
Return on assets TTM -17.42%
Return on equity TTM -28.34%
Profit margin 0%
Book value $21.583
Market capitalisation USD$4.5 billion

TTM: trailing 12 months

Shorting Arena Pharmaceuticals shares

There are currently 3.6 million Arena Pharmaceuticals shares held short by investors – that's known as Arena Pharmaceuticals's "short interest". This figure is 2% down from 3.7 million last month.

There are a few different ways that this level of interest in shorting Arena Pharmaceuticals shares can be evaluated.

Arena Pharmaceuticals's "short interest ratio" (SIR)

Arena Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Arena Pharmaceuticals shares currently shorted divided by the average quantity of Arena Pharmaceuticals shares traded daily (recently around 623867.5257732). Arena Pharmaceuticals's SIR currently stands at 5.82. In other words for every 100,000 Arena Pharmaceuticals shares traded daily on the market, roughly 5820 shares are currently held short.

However Arena Pharmaceuticals's short interest can also be evaluated against the total number of Arena Pharmaceuticals shares, or, against the total number of tradable Arena Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arena Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Arena Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.063% of the tradable shares (for every 100,000 tradable Arena Pharmaceuticals shares, roughly 63 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Arena Pharmaceuticals.

Find out more about how you can short Arena Pharmaceuticals stock.

Arena Pharmaceuticals share dividends

We're not expecting Arena Pharmaceuticals to pay a dividend over the next 12 months.

Have Arena Pharmaceuticals's shares ever split?

Arena Pharmaceuticals's shares were split on a 1:10 basis on 19 June 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arena Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Arena Pharmaceuticals shares which in turn could have impacted Arena Pharmaceuticals's share price.

Arena Pharmaceuticals share price volatility

Over the last 12 months, Arena Pharmaceuticals's shares have ranged in value from as little as $32.95 up to $86.58. A popular way to gauge a stock's volatility is its "beta".

ARNA.US volatility(beta: 1.12)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arena Pharmaceuticals's is 1.1236. This would suggest that Arena Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Arena Pharmaceuticals overview

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, a Phase IIb/III clinical trial for Crohn's disease, and a Phase IIb clinical trial for atopic dermatitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; and APD418 that is in Phase I clinical trial for acute heart failure. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site